Introduction
Drug repurposing for Parkinson's disease has emerged as a critical strategy to accelerate the development of disease-modifying therapies. Multiple international consortia, patient organizations, and research networks have been established to identify, evaluate, and advance existing drugs for Parkinson's treatment. This page provides an overview of the major consortia and their collaborative efforts.
Major Consortia
1. Linked Clinical Trials (LCT) Program
Lead: [Cure Parkinson's](/institutions/cure-parkinsons) (UK)
An international clinical trials program that has reviewed over 200 compounds and advanced 30+ repurposed drugs into clinical trials. The program brings together leading researchers, pharmaceutical companies, and people with Parkinson's to accelerate disease-modifying therapies.
- Established: 2009
- Compounds reviewed: 200+
- Trials initiated: 30+
2. Parkinson's UK Drug Club
Lead: [Parkinson's UK](/institutions/parkinsons-uk) (UK)
A systematic drug screening initiative focusing on approved drugs with potential neuroprotective effects in Parkinson's. The program leverages a network of UK research centers and patient cohorts.
- Established: 2017
- Annual investment: £2-3M
- Active trials: 10+
3. NIH Parkinson's Disease Repurposing Program
Lead: [NINDS](/institutions/nih-ninds) and [NIA](/institutions/nih-nia) (USA)
...Introduction
Drug repurposing for Parkinson's disease has emerged as a critical strategy to accelerate the development of disease-modifying therapies. Multiple international consortia, patient organizations, and research networks have been established to identify, evaluate, and advance existing drugs for Parkinson's treatment. This page provides an overview of the major consortia and their collaborative efforts.
Major Consortia
1. Linked Clinical Trials (LCT) Program
Lead: [Cure Parkinson's](/institutions/cure-parkinsons) (UK)
An international clinical trials program that has reviewed over 200 compounds and advanced 30+ repurposed drugs into clinical trials. The program brings together leading researchers, pharmaceutical companies, and people with Parkinson's to accelerate disease-modifying therapies.
- Established: 2009
- Compounds reviewed: 200+
- Trials initiated: 30+
2. Parkinson's UK Drug Club
Lead: [Parkinson's UK](/institutions/parkinsons-uk) (UK)
A systematic drug screening initiative focusing on approved drugs with potential neuroprotective effects in Parkinson's. The program leverages a network of UK research centers and patient cohorts.
- Established: 2017
- Annual investment: £2-3M
- Active trials: 10+
3. NIH Parkinson's Disease Repurposing Program
Lead: [NINDS](/institutions/nih-ninds) and [NIA](/institutions/nih-nia) (USA)
A coordinated federal initiative leveraging NIH resources to identify and test existing drugs for Parkinson's. The program supports preclinical screening, clinical trials, and biomarker development.
- Established: 2019
- Focus: Disease-modifying therapies
- Key drugs: GLP-1 agonists, TKIs
4. Michael J. Fox Foundation (MJFF) Therapeutic Pipeline
Lead: [Michael J. Fox Foundation](/institutions/michael-j-fox-foundation) (USA)
The world's largest nonprofit funder of Parkinson's research, supporting a comprehensive therapeutic development pipeline including drug repurposing programs.
- Funding: $2B+ total
- Active programs: 50+
- Focus: All therapeutic modalities
Collaborative Networks
International Parkinson's Disease Research Consortium
A network of academic medical centers collaborating on clinical trials across multiple countries, facilitating rapid patient recruitment and data sharing.
| Region | Countries | Trial Centers |
|--------|------------|---------------|
| Europe | UK, Germany, France, Spain | 25+ |
| North America | USA, Canada | 30+ |
| Asia-Pacific | Australia, Japan | 10+ |
Precision Medicine Initiatives
Genetic stratification programs focusing on specific PD subtypes:
- GBA-PD Consortium: Focused on glucocerebrosidase-associated Parkinson's
- LRRK2 Consortium: Leucine-rich repeat kinase 2 research
- SNCA Consortium: [Alpha-synuclein](/proteins/alpha-synuclein) research
Drug Pipeline Summary
Repurposed Drugs in Clinical Development
| Drug | Original Indication | Mechanism | Consortia |
|------|-------------------|-----------|-----------|
| Exenatide | Diabetes | GLP-1R agonist | LCT, NIH, MJFF |
| Ambroxol | Mucolytic | GBA enhancer | LCT, Drug Club |
| Inosine | Gout | Urate elevation | LCT, NIH |
| Nilotinib | Leukemia | [Autophagy](/entities/autophagy) inducer | LCT, NIH |
| Simvastatin | Cholesterol | Neuroprotection | Drug Club, NIH |
| Metformin | Diabetes | AMPK activator | NIH, MJFF |
Collaboration Models
Public-Private Partnerships
Many consortia operate through partnerships with pharmaceutical companies:
- Compound donation programs
- Co-funding arrangements
- Data sharing agreements
Patient Engagement
All major consortia incorporate patient involvement:
- Trial design input
- Recruitment support
- Outcome measure development
Impact Assessment
Key Achievements
| Achievement | Impact |
|-------------|--------|
| Exenatide Phase II success | First positive GLP-1 trial in PD |
| Ambroxol GBA program | First targeted therapy for GBA-PD |
| Inosine SPRING trial | Largest urate elevation study |
| Patient registries | Rapid recruitment for trials |
Research Investment
Total investment in PD drug repurposing across consortia:
- UK: £50M+
- USA: $200M+
- International: $500M+
See Also
- [Drug Repurposing for Neurodegenerative Diseases](/therapeutics/drug-repurposing-neurodegeneration)](/therapeutics)
- [Parkinson's Disease](/diseases/parkinsons-disease)](/proteins/parkin)
- [Cure Parkinson's](/institutions/cure-parkinsons)](/institutions)
- [Parkinson's UK](/institutions/parkinsons-uk)](/institutions)
- [NIH Parkinson's Disease Repurposing Program](/institutions/nih-parkinsons-repurposing-program)](/institutions)
- [Linked Clinical Trials Program](/institutions/linked-clinical-trials-program)](/clinical-trials)
- [Parkinson's UK Drug Club](/institutions/parkinsons-uk-drug-club)
5. Critical Path for Parkinson's (CPP)
The Critical Path for Parkinson's (CPP) consortium, formerly known as the Parkinson's Disease CONSORTIUM, is a public-private partnership focused on accelerating PD therapeutic development through biomarker development and clinical trial optimization[@critical].
Key Activities:
- [Developing PD progression biomarkers](/investment/biomarkers)
- Creating patient-reported outcome measures
- [Optimizing clinical trial designs](/genes/gns)
6. STEADY-PD III Research Program
The Synuclein Imaging as a Diagnostic Marker for Parkinson's Disease (STEADY) program investigates biomarkers for PD diagnosis and progression[@steadypd].
Focus Areas:
- Alpha-synuclein PET imaging
- Fluid biomarker validation
- Early detection markers
7. PD Trials Registry Alliance (PD TRA)
The PD TRA coordinates clinical trial data sharing and patient recruitment across international sites[@trials].
Contributions:
- Clinical trial data harmonization
- Patient matching algorithms
- International site network
8. Lundbeck PD Research Programs
Lundbeck has conducted multiple Phase III trials for PD drug repurposing, including investigative therapies targeting alpha-synuclein aggregation[@lundbeck].
Notable Programs:
- [Alpha-synuclein aggregation inhibitors](/therapeutics/synuclein-aggregation-inhibitors)
- Monoamine oxidase-B inhibitors
- Glutamate modulators
[@critical]: [Critical Path for Parkinson's](https://www.parkinson.org/). Parkinson's Foundation.
[@steadypd]: [STEADY-PD Program](https://www.michaeljfox.org/). Michael J. Fox Foundation.
[@trials]: [PD Trials Registry Alliance](https://clinicaltrials.gov/). ClinicalTrials.gov.
[@lundbeck]: [Lundbeck Parkinson's Research](https://www.lundbeck.com/). Lundbeck Pharmaceuticals.
References
Unknown, Linked Clinical Trials (n.d.)
Unknown, Parkinson's UK Research (n.d.)
Unknown, NINDS Parkinson's Disease Program (n.d.)
Unknown, Michael J. Fox Foundation (n.d.)
Unknown, Critical Path for Parkinson's (n.d.)
Unknown, STEADY-PD Program (n.d.)
Unknown, PD Trials Registry Alliance (n.d.)
Unknown, Lundbeck Parkinson's Research (n.d.)